OOIR: Observatory of International Research

Papers

(The H4-Index of Molecular Neurodegeneration is 46. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-04-01 to 2024-04-01.)

Article	Citations
Mitochondria dysfunction in the pathogenesis of Alzheimer’s disease: recent advances	558
Molecular and cellular mechanisms underlying the pathogenesis of Alzheimer’s disease	425
Relationships of gut microbiota, short-chain fatty acids, inflammation, and the gut barrier in Parkinson’s disease	201
The role of TDP-43 mislocalization in amyotrophic lateral sclerosis	183
Mammalian/mechanistic target of rapamycin (mTOR) complexes in neurodegeneration	108
Neuropathology and molecular diagnosis of Synucleinopathies	105
Neuroimaging advances regarding subjective cognitive decline in preclinical Alzheimer’s disease	105
APOE2: protective mechanism and therapeutic implications for Alzheimer’s disease	104
ApoE in Alzheimer’s disease: pathophysiology and therapeutic strategies	100
Tauopathies: new perspectives and challenges	98
Moving fluid biomarkers for Alzheimer’s disease from research tools to routine clinical diagnostics	98
TDP-43 Pathology in Alzheimer’s Disease	97
A blood-based diagnostic test incorporating plasma Aβ42/40 ratio, ApoE proteotype, and age accurately identifies brain amyloid status: findings from a multi cohort validity analysis	95
Integrated analysis of ultra-deep proteomes in cortex, cerebrospinal fluid and serum reveals a mitochondrial signature in Alzheimer’s disease	95
Proteomic landscape of Alzheimer’s Disease: novel insights into pathogenesis and biomarker discovery	94
Plaque associated microglia hyper-secrete extracellular vesicles and accelerate tau propagation in a humanized APP mouse model	93
“Don’t Phos Over Tau”: recent developments in clinical biomarkers and therapies targeting tau phosphorylation in Alzheimer’s disease and other tauopathies	91
New approaches to symptomatic treatments for Alzheimer’s disease	90
Microbiota in neuroinflammation and synaptic dysfunction: a focus on Alzheimer’s disease	90
Cellular and pathological heterogeneity of primary tauopathies	90
Comprehensive metabolic profiling of Parkinson’s disease by liquid chromatography-mass spectrometry	86
Solving neurodegeneration: common mechanisms and strategies for new treatments	85
METTL3-dependent RNA m6A dysregulation contributes to neurodegeneration in Alzheimer’s disease through aberrant cell cycle events	84
NLRP12 collaborates with NLRP3 and NLRC4 to promote pyroptosis inducing ganglion cell death of acute glaucoma	79
Brain mechanisms underlying neuropsychiatric symptoms in Alzheimer’s disease: a systematic review of symptom-general and –specific lesion patterns	78

Post-infection cognitive impairments in a cohort of elderly patients with COVID-19	77
Glycosphingolipids and neuroinflammation in Parkinson’s disease	76
Oligodendrocyte death and myelin loss in the cuprizone model: an updated overview of the intrinsic and extrinsic causes of cuprizone demyelination	71
Extracellular protein components of amyloid plaques and their roles in Alzheimer’s disease pathology	70
P2RX7 inhibitor suppresses exosome secretion and disease phenotype in P301S tau transgenic mice	68
Neurofilaments in motor neuron disorders: towards promising diagnostic and prognostic biomarkers	68
APOE in the bullseye of neurodegenerative diseases: impact of the APOE genotype in Alzheimer’s disease pathology and brain diseases	66
Plaque-associated human microglia accumulate lipid droplets in a chimeric model of Alzheimer’s disease	64
Microbial-derived metabolites as a risk factor of age-related cognitive decline and dementia	63
Protective genes and pathways in Alzheimer’s disease: moving towards precision interventions	62
Harnessing regulatory T cell neuroprotective activities for treatment of neurodegenerative disorders	56
Microbial involvement in Alzheimer disease development and progression	55
The promise of microRNA-based therapies in Alzheimer’s disease: challenges and perspectives	53
Constitutively active SARM1 variants that induce neuropathy are enriched in ALS patients	53
Impaired NHEJ repair in amyotrophic lateral sclerosis is associated with TDP-43 mutations	52
Adult-onset CNS myelin sulfatide deficiency is sufficient to cause Alzheimer’s disease-like neuroinflammation and cognitive impairment	52
Genome-wide histone acetylation analysis reveals altered transcriptional regulation in the Parkinson’s disease brain	51
Dynamic changes of CSF sTREM2 in preclinical Alzheimer’s disease: the CABLE study	50
The Alzheimer’s disease-associated protective Plcγ2-P522R variant promotes immune functions	48
The CD33 short isoform is a gain-of-function variant that enhances Aβ1–42 phagocytosis in microglia	47
The gut microbiome in Alzheimer’s disease: what we know and what remains to be explored	47
CNS axonal degeneration and transport deficits at the optic nerve head precede structural and functional loss of retinal ganglion cells in a mouse model of glaucoma	46